A Multi-Omics Analysis of PON1 Lactonase Activity in Relation to Human Health and Disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Petrič B;Petrič B; Kunej T; Kunej T; Bavec A; Bavec A
  • Source:
    Omics : a journal of integrative biology [OMICS] 2021 Jan; Vol. 25 (1), pp. 38-51. Date of Electronic Publication: 2020 Dec 11.
  • Publication Type:
    Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101131135 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-8100 (Electronic) Linking ISSN: 15362310 NLM ISO Abbreviation: OMICS Subsets: MEDLINE
    • Publication Information:
      Original Publication: Larchmont, NY : Mary Ann Liebert, Inc., c2002-
    • Subject Terms:
      Disease Susceptibility* ; Gene Expression Regulation, Enzymologic* ; Genomics*/methods ; Homeostasis* ; Proteomics*/methods; Aryldialkylphosphatase/*metabolism; Aryldialkylphosphatase/blood ; Aryldialkylphosphatase/genetics ; Enzyme Activation ; Humans ; Polymorphism, Single Nucleotide
    • Abstract:
      Paraoxonase 1 (PON1) enzyme has antioxidative properties and is present in mammalian blood and several other body fluids. In blood, PON1 is usually integrated into the high-density lipoprotein (HDL) cholesterol. PON1 is a highly versatile enzyme displaying diverse functions such as arylesterase, lactonase, and paraoxonase, among others. PON1 activities are usually investigated with artificial substrates, for example, dihydrocoumarin and thiobutyl butyrolactone for lactonase activity. The PON1 enzyme activities measured with different substrates tend to be falsely assumed as being equivalent in the literature, although there are poor or weak correlations among the PON1 enzyme activities with different substrates. In addition, and despite our knowledge of the factors influencing PON1 paraoxonase and arylesterase activities, there is little knowledge of PON1 lactonase activity variations and attendant mechanisms. This is important considering further that the lactonase activity is the native activity of PON1. We report here a multi-omics analysis of PON1 lactonase activity. The influence of genetic variations, particularly of single nucleotide polymorphisms and epigenetic, proteomic, and lipidomic variations on PON1 lactonase activity are reviewed. In addition, the influence of various environmental, clinical, and demographic variables on PON1 lactonase activity is discussed. Finally, we examine the associations between PON1 lactonase activity and health states and common complex diseases such as atherosclerosis, dementias, obesity, and diabetes. To the best of our knowledge, this is the first multi-omics analysis of PON1 lactonase activity with an eye to future applications in basic life sciences and translational medicine and the nuances of critically interpreting PON1 function with lactones as substrates.
    • References:
      Invest Ophthalmol Vis Sci. 2013 Aug 28;54(8):5852-8. (PMID: 23900603)
      Exp Diabetes Res. 2012;2012:231502. (PMID: 21960992)
      Evid Based Complement Alternat Med. 2012;2012:382763. (PMID: 23243442)
      Biofactors. 2012 Jul-Aug;38(4):292-9. (PMID: 22674772)
      J Lipid Res. 2009 Oct;50(10):2036-45. (PMID: 19091700)
      Redox Rep. 2014 May;19(3):124-32. (PMID: 24620935)
      J Diabetes Res. 2020 Feb 3;2020:3483427. (PMID: 32090118)
      Heredity (Edinb). 2009 Feb;102(2):147-54. (PMID: 18971955)
      Nat Struct Mol Biol. 2004 May;11(5):412-9. (PMID: 15098021)
      Chem Phys Lipids. 2010 Feb;163(2):228-35. (PMID: 19962972)
      Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):482-7. (PMID: 14695884)
      J Lipid Res. 2013 May;54(5):1484-92. (PMID: 23471031)
      Chem Biol Interact. 2016 Nov 25;259(Pt B):160-167. (PMID: 27062891)
      J Clin Med. 2019 Jul 15;8(7):. (PMID: 31311140)
      Nutr Metab Cardiovasc Dis. 2020 Jan 3;30(1):40-48. (PMID: 31757567)
      Atherosclerosis. 2006 Jul;187(1):74-81. (PMID: 16229851)
      Chembiochem. 2006 Jan;7(1):49-53. (PMID: 16329153)
      Biochemistry. 2005 Apr 26;44(16):6371-82. (PMID: 15835926)
      Int J Med Sci. 2018 Oct 20;15(14):1619-1630. (PMID: 30588185)
      Pediatr Res. 2020 Jun 22;:. (PMID: 32570269)
      Clin Chim Acta. 2020 Jan;500:47-53. (PMID: 31626760)
      J Agric Food Chem. 2008 Sep 24;56(18):8704-13. (PMID: 18759451)
      J Enzyme Inhib Med Chem. 2020 Dec;35(1):261-264. (PMID: 31790606)
      J Am Soc Nephrol. 1998 Nov;9(11):2082-8. (PMID: 9808094)
      Gene. 2015 Aug 1;567(1):12-21. (PMID: 25965560)
      Scand J Clin Lab Invest. 2018 Feb - Apr;78(1-2):18-24. (PMID: 29168398)
      Oxid Med Cell Longev. 2018 Nov 5;2018:1752940. (PMID: 30524650)
      Antioxidants (Basel). 2019 Jun 22;8(6):. (PMID: 31234489)
      Gene Ther. 2010 May;17(5):626-33. (PMID: 20182519)
      Obes Res Clin Pract. 2018 Jan - Feb;12(Suppl 2):108-114. (PMID: 27956218)
      Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2041-6. (PMID: 19797705)
      Arch Dermatol Res. 2020 Jan;312(1):33-39. (PMID: 31531730)
      J Cell Biochem. 2018 Jan;119(1):793-805. (PMID: 28657647)
      Indian J Gastroenterol. 2013 Sep;32(5):307-10. (PMID: 23700138)
      Clin Chem Lab Med. 2009;47(4):432-40. (PMID: 19275503)
      J Lipid Res. 2007 Jul;48(7):1637-46. (PMID: 17435182)
      Drug Metab Dispos. 2000 Nov;28(11):1335-42. (PMID: 11038162)
      J Lipids. 2012;2012:587479. (PMID: 22536510)
      Clin Biochem. 2009 Jan;42(1-2):91-8. (PMID: 18977341)
      Biochem Biophys Res Commun. 1998 Jan 14;242(2):249. (PMID: 9446778)
      Mol Genet Metab. 2012 Jan;105(1):141-8. (PMID: 22030099)
      Vasc Health Risk Manag. 2018 Jun 18;14:137-143. (PMID: 29950852)
      Neurotoxicology. 2009 Jul;30(4):628-35. (PMID: 19393262)
      Pharmacogenetics. 2003 Jun;13(6):357-64. (PMID: 12777966)
      J Lipids. 2012;2012:189681. (PMID: 22577559)
      J Clin Biochem Nutr. 2019 May;64(3):250-256. (PMID: 31138960)
      Clin Chem Lab Med. 2011 Jan;49(1):61-7. (PMID: 20961187)
      Biochem Pharmacol. 2005 Feb 15;69(4):541-50. (PMID: 15670573)
      J Assist Reprod Genet. 2019 Aug;36(8):1657-1664. (PMID: 31338723)
      Psychopharmacology (Berl). 2014 Dec;231(24):4703-10. (PMID: 24871701)
      J Clin Lab Anal. 2018 Jan;32(1):. (PMID: 28276605)
      Int J Clin Exp Pathol. 2020 Apr 01;13(4):730-737. (PMID: 32355521)
      Genes Dev. 2009 Apr 1;23(7):781-3. (PMID: 19339683)
      Curr Neuropharmacol. 2019;17(11):1004-1020. (PMID: 30592255)
      Clin Chim Acta. 2015 May 20;445:41-7. (PMID: 25801214)
      Br J Nutr. 2013 Nov 14;110(9):1639-47. (PMID: 23789921)
      J Alzheimers Dis. 2015;46(1):179-86. (PMID: 25720407)
      BMC Vet Res. 2014 Mar 25;10:74. (PMID: 24666514)
      Acta Biochim Pol. 2016;63(3):511-5. (PMID: 27337219)
      OMICS. 2017 Jan;21(1):1-16. (PMID: 28271979)
      Environ Int. 2020 May;138:105609. (PMID: 32114288)
      Toxicology. 2019 Jan 1;411:24-31. (PMID: 30359673)
      BMC Vet Res. 2013 Apr 11;9:73. (PMID: 23578174)
      Clin Biochem. 2013 Dec;46(18):1830-6. (PMID: 24028901)
      Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (PMID: 29126136)
      Int J Clin Pract. 2019 Jun;73(6):e13315. (PMID: 30681756)
      J Atheroscler Thromb. 2016;23(2):225-32. (PMID: 26447089)
      Redox Rep. 2014 Jul;19(4):161-9. (PMID: 24533892)
    • Contributed Indexing:
      Keywords: atherosclerosis; dementias; diabetes; genomics; lactonase; multi-omics; obesity; paraoxonase 1; proteomics
    • Accession Number:
      EC 3.1.8.1 (Aryldialkylphosphatase)
      EC 3.1.8.1 (PON1 protein, human)
    • Publication Date:
      Date Created: 20201211 Date Completed: 20211203 Latest Revision: 20211214
    • Publication Date:
      20240104
    • Accession Number:
      PMC8045895
    • Accession Number:
      10.1089/omi.2020.0160
    • Accession Number:
      33306925